エピソード

  • First Dual-Agent Eye Drop for Presbyopia Approved

    First Dual-Agent Eye Drop for Presbyopia Approved
    2026/02/04
    The FDA approves the first dual-agent eye drop for presbyopia; Rayner launches a personalized, AI-powered patient education platform; and new study examines the link between sleep positioning and eye pressure. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    7 分
  • FDA Approves Label Supplement for iDose TR

    FDA Approves Label Supplement for iDose TR
    2026/01/28
    The FDA approves a key label supplement for Glaukos’ iDoseTR; Nidek announces the European launch of a new open-field refraction system; and there have been several leadership changes announced during the first month of 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    6 分
  • Rayner Launches New Phaco System

    Rayner Launches New Phaco System
    2026/01/21
    Rayner launches a new phaco system in the US; Eylea 8 mg is approved for a third indication in Europe; and Nanodropper announces a consolidation plan to expand its offerings under a new name. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    4 分
  • Moorfields Researchers Reveal Promising Treatment for Hypotony

    Moorfields Researchers Reveal Promising Treatment for Hypotony
    2026/01/14
    New research may provide hope for patients with a rare vision-threatening condition; the first daily disposable soft contact lens using EDOF technology for presbyopia is cleared in the US; and there several advancements made in the clinical development of treatment candidates for retinal diseases. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    10 分
  • Staar Terminates Merger with Alcon

    Staar Terminates Merger with Alcon
    2026/01/07
    Shareholders vote on Alcon’s blockbuster acquisition proposal for Staar Surgical; the FDA responds to Outlook’s latest BLA submission for wet AMD drug Lytenava; and the FDA approves an interchangeable biosimilar to Lucentis. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    12 分
  • 2025 Year in Review - Part 2

    2025 Year in Review - Part 2
    2025/12/31
    Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    9 分
  • 2025 Year in Review - Part 1

    2025 Year in Review - Part 1
    2025/12/24
    There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    10 分
  • Update on Reproxalap PDUFA Timing

    Update on Reproxalap PDUFA Timing
    2025/12/17
    Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    9 分